

Form PTO-1449  <b>INFORMATION DISCLOSURE STATEMENT</b>				Atty. Docket: 452005-150		Serial No.: Unassigned	
				Applicant: Bulwani <i>et al.</i>			
				Filing Date: September 17, 2003		Group: Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Sub- Class	Filing Date
/KC/		6,462,094	10/8/02	Dang et al.	514	849	8/22/01
/KC/		6,417,206 B1	7/9/02	Leflein et al.	514	352	1/26/01
/KC/		6,306,904 B1	10/23/01	Gordziel	514	530	7/25/00
/KC/		6,287,597 B1	9/11/01	Gordziel	424	464	3/12/99
/KC/		6,037,358	3/14/00	Gordziel	514	357	3/24/99
/KC/		5,807,579	9/15/98	Vilkov et al.	424	469	11/14/96
/KC/		5,663,415	9/2/97	Chopdekar et al.	560	68	6/28/96
/KC/		5,599,846	2/4/97	Chopdekar et al.	514	653	6/28/96
/KC/		5,164,398	11/17/92	Sims et al.	514	282	4/1/91
/KC/		4,601,714	7/22/86	Burnhill	604	286	3/7/84
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Country	Class	Sub- Class	Translation
/KC/		64,007,786 (abstract)	8-31-93	JP	_____	_____	
/KC/		06287144	01-02-95	JP	_____	_____	
/KC/		39007786	05-18-64	JP	_____	_____	YES
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
/KC/		Weiler et al., "Randomized, double blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinitis using an acute model," <i>Annals of Allergy</i> , vol. 64(1): 63-67					
/KC/		Goldberg et al., "Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders," <i>Clinical Medicine</i> , vol. 72(9): 1475-1479.					
/KC/		TRIPLE TANNATE, Drug Launches (doc. #: 0182701) 5/99					
/KC/		TUSSI-12, Drug Launches (doc. #: 0179128) 3/99					
/KC/		TUSSI-12, Drug Launches (doc. #: 0176901) 12/98					
Examiner: /Kendra Carter/				Date Considered: 01/25/2008			
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

Form PTO-1449  <b>INFORMATION DISCLOSURE STATEMENT</b>				Atty. Docket: 452005-150		Serial No.: Unassigned	
				Applicant: Bulwani et al.			
				Filing Date: September 17, 2003		Group: Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date	
/KC/	B1 4552,899	10/20/92	Sunshine et al.	514	568	4/9/84	
/KC/	4,552,899	11/12/85	Sunshine et al.	514	568	4/9/84	
/KC/	3,061,517	10/30/62	Walter	167	65	2/16/62	
/KC/	3,018,221	1/23/62	Millar et al.	167	65	3/28/58	
/KC/	2,798,024	7/2/57	Zappas et al.	167	82	6/2/54	
/KC/	2,757,124	7/31/56	Wolff	167	82	3/8/52	
/KC/	20010011104	8/2/01	Gordziel	514	653	12/11/98	
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
/KC/	R-TANNATE, Drug Launches (doc. #: 0172212) 8/98						
/KC/	TRIPLE TANNATE, Drug Launches (doc. #: 0163340). 1/98						
/KC/	ATROHIST, Drug Launches (doc. #: 0154800). 5/97						
/KC/	GELHIST, Drug Launches (doc. #: 015445). 5/97						
/KC/	PHENATAN, Drug Launches (doc. #: 0149758) 1/97						
/KC/	TRIOTANN, Drug Launches (doc. #: 0136052) 12/95						
/KC/	TRI-TANNATE, Drug Launches (doc. #: 0129566) 6/95						
/KC/	RICOBIN-D, Drug Launches (doc. #: 0129564) 6/95						
/KC/	RICOBID, Drug Launches (doc. #: 0129563) 6/95						
/KC/	QUAD-TUSS TANNATE, Drug Launches (doc. #: 0127440) 4/95						
/KC/	TRI-TANNATE, Drug Launches (doc. #: 0179121) 3/99						
/KC/	TRITAN, Drug Launches (doc. #: 0144945) 9/96						
/KC/	TRI-NATAN, Drug Launches (doc. #: 0110372) 11/93						
/KC/	R-TANNATE, Drug Launches (doc. #: 0110158) 11/93						
/KC/	TRIN TUSS, Drug Launches (doc. #: 0049139) 3/93						
Examiner: /Kendra Carter/				Date Considered: 01/25/2008			
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

[illegible]